Those patents entitle it to a cut of every smartphone sold worldwide. The company generates most of its revenue by selling mobile chipsets, but most of its profits come from its portfolio of wireless patents. This ruling raises tough questions about Qualcomm's future. The court ruled that Qualcomm "strangled competition" with "unreasonably high" royalty rates, anti-competitive bundling strategies, and exclusive partnerships. Federal Trade Commission won its antitrust case against Qualcomm, the largest mobile-chip maker in the world. Leo Sun (Qualcomm): In late May, the U.S. With key steps in making that Celgene buyout a reality on the way and an important update for Opdivo right around the corner, keep your eyes on Bristol-Myers Squibb. BMS will pick up several potential blockbusters with the Celgene acquisition, including liso-cel, one of the most valuable pipeline drugs in development right now. Market researcher EvaluatePharma projects that two of the five biggest blockbusters of the future are drugs in BMS' lineup: Opdivo and Eliquis. CFO Charles Bancroft said in the company's Q1 conference call that the results from this study will be announced this summer. There might not be any hard news on this divestiture in July, but it wouldn't be surprising if rumors emerge about which company might pick up the blockbuster immunology drug.Īnother thing to look forward to from BMS is its announcement of results from a phase 3 clinical study evaluating a combination of Opdivo and Yervoy as a first-line treatment for non-small cell lung cancer. The drugmaker recently announced that it intends to sell Celgene's psoriasis and psoriatic arthritis drug, Otezla, which raked in $1.6 billion last year, in an effort to clear the way for winning a thumbs-up from regulators for the acquisition. Now BMS must secure the necessary regulatory approvals. Shareholders of both companies have already approved the deal. There are plenty of things to watch with BMS in July and in the following months.īy far the biggest upcoming event for BMS is its pending acquisition of Celgene (NASDAQ: CELG). Keith Speights (Bristol-Myers Squibb): Bristol-Myers Squibb (BMS) is anything but a boring big pharma stock.
0 Comments
Leave a Reply. |